GEN Feature Articles
Supplement: Who Gets Immunotherapy for Cancer?
Single-agent or combination checkpoint inhibition (CPI) immunotherapy can have dramatic impacts for positive responders. But currently-used nonspecific biomarkers are unable to definitively stratify and identify cohorts. This is a critical challenge; no one wants to deny care. Targeted biomarkers and companion diagnostics can greatly aid therapeutic decision making. Immunotherapy applications require more than just quantification of infiltrating immune cell subpopulations. Context is crucial, and concentrated efforts are underway to provide accurate information on the percentage and location of infiltrating immune cell subpopulations, both relative to each other and to tumor margins, as well as levels of expression of checkpoint and other immune markers. The Cell IDx UltraPlex mxIF (multiplex immunofluorescence) technology, a simple two-hour staining procedure, can simultaneously detect multiple biomarkers in tissue using a standard two-step primary and secondary antibody protocol and existing autostainers, imaging scanners, and image-analysis software. The technology is modular (plug and play); approximately 30 primary antibodies have been qualified thus far. Read the full article from GEN.